Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma

被引：3
|
作者：
Fenk, R
Hoyer, B
Steidl, U
Kondakci, M
Graef, T
Heuk, R
Ruf, L
Strupp, C
Neumann, F
Rohr, UP
Hildebrandt, B
Haas, R
Kobbe, G
机构：
[1] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany
[2] Harvard Univ, Inst Med, Div Hematol Oncol, Boston, MA 02115 USA
[3] Univ Dusseldorf, Dept Human Genet & Anthropol, D-40225 Dusseldorf, Germany
来源：
LEUKEMIA | 2005年 / 19卷 / 01期
关键词：
D O I：
10.1038/sj.leu.2403564
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：156 / 159
页数：5
相关论文
共 50 条
  • [31] Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy
    Biran, Noa
    Sehgal, Priya
    Sahni, Gagan
    Doucette, John
    Chari, Ajai
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : E125 - E127
  • [32] Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study
    Feyler, Sylvia
    Rawstron, Andy
    Jackson, Graham
    Snowden, John A.
    Cocks, Kim
    Johnson, Roderick J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 139 (03) : 429 - 433
  • [33] Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma
    Sampson, FC
    Beard, SM
    Scott, F
    Vandenberghe, E
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1015 - 1019
  • [34] Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
    Badros, AZ
    Siegel, E
    Bodenner, D
    Zangari, M
    Zeldis, J
    Barlogie, B
    Tricot, G
    AMERICAN JOURNAL OF MEDICINE, 2002, 112 (05): : 412 - 413
  • [35] The role of thalidomide in myeloma patients eligible for high-dose therapy
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 28 - 29
  • [36] Daily low dose thalidomide plus monthly high-dose dexamethasoneas consolidation/maintenance treatment in elderly multiple myeloma patients
    Gentile, M.
    Mazzone, C.
    Iorio, C.
    Lucia, E.
    Vigna, E.
    Mazzei, F.
    Carnevale, P.
    Bisconte, M. G.
    Gentile, C.
    Morabito, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 93 - 93
  • [37] An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma
    Prince, H. Miles
    Schenkel, Brad
    Mileshkin, Linda
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 46 - 55
  • [38] Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: A systematic review.
    Prince, M
    Adena, M
    Smith, DK
    Hertel, J
    BLOOD, 2005, 106 (11) : 373B - 373B
  • [39] High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
    Samur, Mehmet Kemal
    Roncador, Marco
    Samur, Anil Aktas
    Fulciniti, Mariateresa
    Bazarbachi, Abdul Hamid
    Szalat, Raphael
    Shammas, Masood A.
    Sperling, Adam S.
    Richardson, Paul G.
    Magrangeas, Florence
    Minvielle, Stephane
    Perrot, Aurore
    Corre, Jill
    Moreau, Philippe
    Thakurta, Anjan
    Parmigiani, Giovanni
    Anderson, Kenneth C.
    Avet-Loiseau, Herve
    Munshi, Nikhil C.
    BLOOD, 2023, 141 (14) : 1724 - 1736
  • [40] Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment
    Sonneveld, P
    Segeren, CM
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 9 - 18
12345